Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 0.65 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739233 | 1.00 | PDE9A (0.65) | PDE9APDE1CKCNH2 | |
| SCHEMBL2995922 | 0.98 | PDE9A (0.62) | PDE9APDE1CKCNH2 | |
| SCHEMBL2995909 | 0.98 | PDE9A (0.62) | PDE9APDE1CKCNH2 | |
| SCHEMBL2989109 | 0.91 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL2989116 | 0.91 | PDE9A (0.59) | PDE9APDE1C | |
| SCHEMBL14997318 | 0.84 | PDE9A (0.76) | PDE9APDE1CKCNH2 | |
| SCHEMBL3099231 | 0.83 | PDE9A (0.74) | PDE9APDE1CKCNH2 | |
| SCHEMBL3103433 | 0.83 | PDE9A (0.74) | PDE9APDE1CKCNH2 | |
| SCHEMBL2996105 | 0.82 | PDE9A (0.73) | PDE9APDE1CKCNH2 | |
| SCHEMBL2993302 | 0.82 | PDE9A (0.73) | PDE9APDE1CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969744-B2 | Compounds for use in cognition improvement | FUNDACIÓN LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2018-05-15 | — | — | US | disclosed |
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-03 | — | — | US | disclosed |
| EP-3177622-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | Fundacion para la Investigacion Medica Aplicada (ES) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020307-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-02-11 | — | — | WO | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8618117-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2389382-B1 | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217973-A1 | NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT | CHAT, NLN, GRIN2C | PDE9A 2393/4885PDE1C 1500/4885KCNH2 3972/4885 |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | PDE9A 1/4885PDE1C 28/4885KCNH2 1791/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | PDE9A 1/4885PDE1C 28/4885KCNH2 1791/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | PDE9A 1/4885PDE1C 28/4885KCNH2 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.